TransMedics Group is trading 13.6% down at $72.44 after its Q2 2026 earnings report showed an EPS miss driven by a 49% surge in operating expenses.
- The company reported strong 21% year-over-year revenue growth and beat revenue estimates, prompting management to raise the low end of its full-year 2026 revenue guidance.
- Despite the top-line growth, investors are focused on margin pressure and profitability concerns related to a strategic pivot toward higher-cost global logistics services.